Clinical Report: Evaluating Serum Resistin Levels as a Potential Indicator for Assessing Coronary Heart Disease Severity

Overview

This study systematically quantifies the relationship between serum resistin levels and coronary heart disease (CHD) severity. Findings indicate a progressive increase in resistin levels correlating with disease severity, suggesting its potential as a biological marker.

Background

Coronary heart disease (CHD) remains a leading cause of morbidity and mortality globally, necessitating improved diagnostic and risk stratification tools. Chronic inflammation plays a crucial role in the progression of atherosclerosis, with resistin identified as a key adipokine involved in inflammatory processes. Understanding the relationship between resistin levels and CHD severity could enhance clinical management strategies.

Data Highlights

Key Findings

• Serum resistin levels increase progressively from healthy controls to stable CHD, ACS, and AMI.
• Standardized mean differences indicate significant elevation in resistin levels correlating with disease severity.
• Substantial heterogeneity (I²=95.8%) and publication bias were observed in the analysis.
• Resistin is not recommended as a standalone diagnostic tool due to potential overestimation of effect sizes.
• Potential clinical utility of resistin may lie in multi-biomarker models for risk stratification.

Clinical Implications

Clinicians should consider serum resistin levels as part of a broader assessment of CHD severity rather than a standalone marker. The findings underscore the need for further validation in large-scale studies to establish resistin's role in clinical practice.

Conclusion

Serum resistin levels demonstrate a clear association with CHD severity, but significant methodological concerns limit its current clinical applicability. Future research is essential to validate its use in risk stratification models.

Related Resources & Content

1. Frontiers | Serum Resistin as a Potential Biomarker for Stratifying the Severity of Coronary Heart Disease: A Network Meta-Analysis
2. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease - American College of Cardiology
3. The Journal of Clinical Endocrinology & Metabolism — Elevated Circulating Resistin Levels Associated with Increased Risk of Sarcopenia in Elderly Individuals
4. Clinical Research in Cardiology — Reduced levels of circulating microRNAs in heart failure patients correlate with atherosclerotic conditions and increased rates of cardiovascular rehospitalization
5. European Journal of Preventive Cardiology — High-sensitivity C-reactive protein: just measure it!
6. Clinical Rheumatology — Adipokine Levels and Metabolic Syndrome in Patients with Systemic Lupus Erythematosus and Systemic Sclerosis
7. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease - American College of Cardiology
8. Frontiers | Serum Resistin as a Potential Biomarker for Stratifying the Severity of Coronary Heart Disease: A Network Meta-Analysis
9. Phenotyping atherosclerotic plaque and perivascular adipose tissue: signalling pathways and clinical biomarkers in atherosclerosis | Nature Reviews Cardiology